C07K 2319/055
Containing a signal for localisation to secretory granules
Official title: containing a signal for localisation to secretory granules (for exocytosis)
C07K2319/055 (Containing a signal for localisation to secretory granules) appears on 39 US grants and 75 published applications in this corpus.
Search patents in C07K- Granted patents
- 39
- Published applications
- 75
- Assignees
- 48
- Inventors
- 122
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 4 |
| 2005 | 1 | 0 |
| 2006 | 1 | 1 |
| 2007 | 1 | 3 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 2 | 3 |
| 2012 | 1 | 3 |
| 2013 | 0 | 3 |
| 2014 | 1 | 4 |
| 2015 | 3 | 1 |
| 2016 | 3 | 3 |
| 2017 | 3 | 4 |
| 2018 | 4 | 2 |
| 2019 | 2 | 6 |
| 2020 | 1 | 2 |
| 2021 | 2 | 11 |
| 2022 | 1 | 4 |
| 2023 | 2 | 3 |
| 2024 | 6 | 7 |
| 2025 | 3 | 5 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Engineered extracellular vesicles comprising fusion proteins12 Aug 2025US 12,384,828 B2Diadem Biotherapeutics Inc.
- Anti-NGF antibodies and uses thereof5 Aug 2025US 12,378,308 B2Invetx, Inc.
- ICAM-1 targeted fusion enzymes3 Jun 2025US 12,319,719 B2University of Maryland, College Park
- Anti-NGF antibodies and uses thereof8 Oct 2024US 12,110,322 B2Invetx, Inc.
- Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins24 Sep 2024US 12,097,257 B2New York University
- Sars-cov-2 immunogenic compositions and methods2 Jul 2026US 2026/0183383 A1Capricor, Inc.
- Trafficked rnas for assessment of cell-cell connectivity and neuroanatomy12 Mar 2026US 2026/0071269 A1President and Fellows of Harvard College
- Active loading of cargo entity into lipid bilayer particles using dimerization domains9 Oct 2025US 2025/0313815 A1Northwestern University
- Icam-1 targeted fusion enzymes14 Aug 2025US 2025/0257105 A1University of Maryland, College Park
- Artificial synapses22 May 2025US 2025/0163126 A1Diadem Biotherapeutics Inc.
Most cited
By later US patents
- Method for generating split, non-transferable genes that are able to express an active protein product22US 6,858,775 B1New England Biolabs, Inc. · 2005
- Fusion proteins12US 9,243,301 B2Allergan, Inc. · 2016
- Production of sialylated N-glycans in lower eukaryotes10US 7,863,020 B2GlycoFi, Inc. · 2011
- Hybrid molecules and their use for optically detecting changes in cellular microenvironments8US 7,094,888 B2Memorial Sloan Kettering Cancer Center · 2006
- Treatment of pain7US 9,072,736 B2Allergan, Inc. · 2015